Sensitivity and specificity of mean platelet volume as a laboratory marker for irritable bowel syndrome: Can it be added to Rome criteria?

Abstract

Background Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder. Objective This study aimed to evaluate red blood cell distribution width (RDW) and mean platelet volume (MPV) as laboratory markers to discriminate IBS patients from both healthy controls and patients with inflammatory bowel disease (IBD). Methods This case-control study enrolled patients referred to Ayatollah Rouhani Hospital, Endoscopy Department, Babol, Iran, for colonoscopy examination from 2015 to 2017. Fifty IBS patients were selected from among patients who had undergone a normal colonoscopy and showed symptoms matching the Rome III criteria. Fifty healthy participants and 50 IBD patients, matched for sex and age, were also enrolled in this study. Both RDW and MPV were measured and analysed by independent sample t -test and receiver operating characteristic curve analysis. A p -value of less than 0.05 was considered statistically significant. Results While RDW was higher and MPV was lower among IBS patients compared to healthy controls ( p = 0.047 and p = 0.001), there were no significant differences in RDW or MPV levels between IBS and IBD patients. The area under the curve of RDW in the discrimination between IBS and IBD was 0.620 ( p = 0.039), and the area under the curve of MPV in the discrimination between healthy controls and IBS patients was 0.801 ( p = 0.001). Conclusion Mean platelet volume is potentially a useful laboratory marker for distinguishing between IBS patients and healthy individuals. Red blood cell distribution width should be considered as a potential marker to distinguish among IBS and IBD patients.

From inflammatory bowel disease to colorectal cancer: what’s the role of miRNAs?

“…Despite many studies, the exact mechanisms of IBD pathogenesis are still unclear. Diagnosis and monitoring of the disease has always been a serious challenge, thus many studies have focused on identifying appropriate biomarkers for diagnosis and monitoring patients [ 4 – 7 ]. Besides, Ulcerative colitis and Crohn’s disease are also very similar in clinical, endoscopic and histological features, and it is difficult to differentiate between the two diseases and is a serious challenge for gastroenterologists.…”

Plateletcrit for predicting prognosis in patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloid

“…There is growing recognition of the critical role of platelets in inflammation and immune responses of various diseases, such as nasal polyps, 11 type 2 diabetes mellitus, 12 lumbar disc hernias, 13 autoimmune liver diseases, 14 and irritable bowel syndrome. 15 Plateletcrit is also one of these platelet parameters and is associated with various conditions, including rheumatoid arthritis 16 and papillary thyroid cancer. 17 At present, it remains challenging to use blood indicators to predict the prognosis of HSOS, especially in an earlier stage.…”